AIG01 / AIGEN Sci - LARVOL DELTA

Discovery of a novel SOS1 inhibitor, AIG01012, targeting pan-KRAS mutant cancers (AACR 2024) - "Moreover, AIG01012 showed synergistic antiproliferative effects when combined with approved drugs such as sotorasib (for lung cancer with KRAS mutations), trametinib (a MEK inhibitor), and Osimertinib (targets specific EGFR mutations) in either H358 or PC-9 cell lines. In summary, utilizing our human-in-the-loop (HITL) AI platform, AIGEN ChemTailor, we have efficiently derived AIG01012 as a potent SOS1 inhibitor that targets a wide range of KRAS interactions. With its notable in vitro and in vivo outcomes, AIG01012 is set for further exploration and prospective clinical trials as a significant contender in KRAS-targeted cancer treatments."

Lung Cancer • Oncology • Solid Tumor • EGFR • KRAS